Paolo Tarantino: A Bridge Between Chemotherapy of the Past and the Biological Therapies of the Present
Paolo Tarantino shared on X:
“Conjugated Antibodies: A Bridge Between Chemotherapy of the Past and the Biological Therapies of the Present, Which Gives Thousands of Cancer Patients a Future Every Year. An Honor to Have the Opportunity to Talk to Daniela Cipolloni of Presa Diretta.
Link to the Service.”
Proceed to the video attached to the post.
Source: Paolo Tarantino/X
More posts featuring Paolo Tarantino on oncodaily.com
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023